Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine L Nathanson

Showing results (1-10 of 372) with videos related to

Pageof 38
Sort By:
Biochemical Pharmacology|April 24, 2010
Using genetics and genomics strategies to personalize therapy for cancer: focus on melanomaKatherine L Nathanson
The New England Journal of Medicine|November 19, 2010
Taking the guesswork out of uveal melanomaMeenhard Herlyn, Katherine L Nathanson
Cancer Genetics|March 21, 2012
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic backgroundLauren Fishbein, Katherine L Nathanson
JAMA Oncology|April 7, 2017
Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of DiseaseLauren Fishbein, Katherine L Nathanson
Current Opinion in Endocrine and Metabolic Research|September 27, 2024
Molecular Genetics of Pheochromocytoma/ParagangliomaHeather Wachtel, Katherine L Nathanson
Cancer Biology & Therapy|January 11, 2005
Somatic genetic changes in association with testicular germ cell tumor prognosisKatherine L Nathanson, David J Vaughn
Annual Review of Genomics and Human Genetics|May 16, 2017
Application of Panel-Based Tests for Inherited Risk of CancerPayal D Shah, Katherine L Nathanson
Nature Medicine|September 10, 2013
Immunotherapy at large: the road to personalized cancer vaccinesRobert H Vonderheide, Katherine L Nathanson
Seminars in Oncology|December 1, 2016
Genetic changes associated with testicular cancer susceptibilityLouise C Pyle, Katherine L Nathanson
Haematologica|July 20, 2023
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly relatedPayal D Shah, Katherine L Nathanson
Pageof 38

Showing results (1-10 of 372) with videos related to

Sort By:
Pageof 38
Biochemical Pharmacology|April 24, 2010
Using genetics and genomics strategies to personalize therapy for cancer: focus on melanomaKatherine L Nathanson
The New England Journal of Medicine|November 19, 2010
Taking the guesswork out of uveal melanomaMeenhard Herlyn, Katherine L Nathanson
Cancer Genetics|March 21, 2012
Pheochromocytoma and paraganglioma: understanding the complexities of the genetic backgroundLauren Fishbein, Katherine L Nathanson
JAMA Oncology|April 7, 2017
Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of DiseaseLauren Fishbein, Katherine L Nathanson
Current Opinion in Endocrine and Metabolic Research|September 27, 2024
Molecular Genetics of Pheochromocytoma/ParagangliomaHeather Wachtel, Katherine L Nathanson
Cancer Biology & Therapy|January 11, 2005
Somatic genetic changes in association with testicular germ cell tumor prognosisKatherine L Nathanson, David J Vaughn
Annual Review of Genomics and Human Genetics|May 16, 2017
Application of Panel-Based Tests for Inherited Risk of CancerPayal D Shah, Katherine L Nathanson
Nature Medicine|September 10, 2013
Immunotherapy at large: the road to personalized cancer vaccinesRobert H Vonderheide, Katherine L Nathanson
Seminars in Oncology|December 1, 2016
Genetic changes associated with testicular cancer susceptibilityLouise C Pyle, Katherine L Nathanson
Haematologica|July 20, 2023
<i>BRCA1/2</i> mutations and <i>de novo</i> hematologic malignancies: true, true and not clearly relatedPayal D Shah, Katherine L Nathanson
Pageof 38